Bioversys published Phase IIa early bactericidal activity data for alpibectir (BVL‑GSK098) combined with ethionamide in pulmonary tuberculosis in the New England Journal of Medicine, reporting the first clinical proof‑of‑concept for the combination. The results showed meaningful bactericidal activity in patients, supporting further development. The NEJM publication gives the regimen scientific credibility and may accelerate partner interest and regulatory engagement. Tuberculosis drug development prioritizes regimens that shorten treatment and overcome resistance; Bioversys’ data will be evaluated for potency, safety, and potential to integrate into multi‑drug regimens for drug‑resistant TB.